Dedham, MA — [ December 15, 2025 ] — Synterex, a WBENC- and DOBE-certified consulting firm specializing in AI-enabled regulatory and clinical writing, announced that AgileWriter.ai®, the flagship module of the company’s AgileSuite™ digital regulatory ecosystem, has joined the Veeva AI Partner Program.  The collaboration will integrate AgileWriter with Veeva RIM, part of the Veeva Development Cloud—the technology foundation that streamlines data and processes across clinical,

The FDA’s move toward single-trial approvals raises the stakes for every pivotal clinical trial. Learn how AI-driven documentation helps teams accelerate and stay compliant.

In today’s high-stakes biopharma environment, speed, compliance, and precision define success. For regulatory and medical-writing teams, optimizing submission-ready content is no longer just operational—it’s strategic. With AI-powered regulatory documentation systems, companies can align earlier with submission requirements, anticipate reviewer expectations, and dramatically reduce rework and costly delays. The result: accelerated approvals, extended runway, and preserved opp

TL;DR: FDA’s new Commissioner’s National Priority Voucher (CNPV) program  accelerates reviews to ~1–2 months for products that advance U.S. national priorities: big-burden diseases, public-health crises, affordability, and on-shored manufacturing. If you’re heading into this pathway, success hinges on early CMC and labeling completeness, disciplined traceability, and an operating model built for rapid, team-based review.   What’s inside the program  Why it exists:  Speed acce

Azure-hosted AI platform revolutionizes clinical and regulatory writing with automation, traceability, and explainable AI.  Dedham, MA — November 21, 2025 — Synterex, Inc. , a global c onsulting firm specializing in clinical and regulatory operations, agile methodologies, and AI-driven technologies, has announced the availability of its flagship solution, AgileWriter.ai® , on the Microsoft Azure Marketplace. This launch expands access to Synterex’s AI-powered regulatory-writi

Machine learning is transforming clinical trial monitoring from slow, manual oversight into real-time, predictive decision-making. As decentralized designs, digital biomarkers, and regulatory expectations evolve, the industry is entering a new era where data integrity, responsiveness, and automation are no longer optional—they’re essential.

Discover how EMA and FDA are transforming from reviewers to data-platform operators—and how sponsors and writers must adapt to real-time evidence exchange and continuous review.

Explore how the EMA’s 2025 Real-World Evidence Framework is reshaping regulatory submissions—and what it means for medical writers navigating structured data and evolving reviewer expectations.

Explore the real costs, risks, and ROI of building versus buying an AI-powered regulatory documentation system—and why a hybrid approach often wins

Understanding AI Technologies AI technologies have made significant strides in recent years. Generative AI, in particular, has changed how we approach various tasks. From content creation to data analysis, AI is becoming an indispensable tool. However, to maximize its potential, we must understand the nuances of its operation. The Importance of AI in Biotech and Pharma In the biotech and pharmaceutical sectors, AI can streamline processes, enhance accuracy, and improve compli

Learn how Synterex helps biotechs turn regulatory uncertainty into advantage through expert strategy, automation, and AI-enabled efficiency.

In 2025, several major pharmaceutical companies — including MSD (Merck), AstraZeneca, and Eli Lilly — have scaled back or cancelled planned investments in the UK. Decisions have ranged from pausing vaccine-manufacturing expansions to abandoning research center projects.